Universal Ibogaine Receivables

Universal Ibogaine (IBOGF) currently reports a receivables of $610K as of April 2025. That compares with $220K in the prior-year period — up 178.9% year over year. Use the charts on this page to explore Universal Ibogaine's receivables history and peer comparisons.

Universal Ibogaine's receivables increased from $220K to $610K — a 178.9% year-over-year increase (period ending April 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Universal Ibogaine reported $610K in receivables as of April 2025. That compares with $220K in the prior-year period — up 178.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $610K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Universal Ibogaine, and consider following IBOGF for alerts when major investors trade the stock.

Universal Ibogaine is classified in the Healthcare sector. On receivables, it currently shows $610K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBOGF with unrelated industries.